As illustrated in this Spotlight Issue, protein degradation by the UPS plays a central role in cardiovascular physiology and disease: from endothelial function, the cell cycle, and atherosclerosis to myocardial ischaemia, cardiac hypertrophy, inherited cardiomyopathies, and heart failure.
Investigations on the role of the UPS in the cardiovascular system started about 15 years ago and have since increased exponentially. In the heart, the first reports demonstrated that the proteasome is responsible for the degradation of specific, stress-sensitive transcriptional regulators, such as NF-kB, HIF-1a, or inducible cAMP early repressor. 3, 4 It was subsequently shown that the UPS also degrades contractile proteins and components of the sarcomere. 5, 6 The development of several categories of proteasome-specific inhibitors further delineated a role for the UPS in multiple forms of heart disease, such as ischaemia/reperfusion, cardiac hypertrophy, cardiomyopathies, and heart failure. In the vasculature, it was initially shown that proteasome activity affects angiogenesis 7 and, subsequently, that the proteasome participates in nitric oxide metabolism, oxidative stress, and atherosclerosis. Descriptions of a dysfunction of the UPS in human heart disease also began to emerge in the literature. 8 -10 Recently, several clinical case reports have mentioned potentially cardiotoxic side effects of proteasome inhibitors, for example, in patients treated for solid tumours and haematological malignancies. 11, 12 All these advances have been reviewed in the current Spotlight Issue dedicated to the role of the ubiquitin-proteasome pathway in cardiovascular disease. This issue covers three main aspects of the UPS in the cardiovascular system: protein quality control, the role of the UPS in vascular function, and the role of the UPS in heart disease. Throughout the issue, we have tried to emphasize the paradoxes and controversies that still characterize this field of investigation, in particular in terms of the physiological consequences of UPS activation vs. inhibition.
In the first two articles, Su and Wang 13 as well as Dantuma and Lindsten, 14 review the importance of the UPS in quality control mechanisms of protein production. These control mechanisms include minimizing the production of non-functional proteins and degrading misfolded and denatured proteins. It is estimated that under normal conditions up to 50% of nascent proteins will be degraded by the proteasome even before peptide elongation is achieved. 15 The authors emphasize how this crucial function of the UPS can be perturbed by cytotoxic stress 14 and how proteasome insufficiency may lead to heart failure. 13 A key concept is that UPS insufficiency will permit aberrant protein aggregation and will lead to the accumulation of unwanted proteins in cardiomyocytes. This 'cardiac proteinopathy' may in the long run contribute to ventricular dysfunction and failure. Su and Wang also highlight the emerging importance of functional interplay between the UPS and autophagy, another mechanism of protein degradation. 13 It is noteworthy that, as for the UPS, it remains controversial whether activation or inhibition of autophagy may prove beneficial for cardiac cell survival. The next few articles address different roles of the UPS in vascular function and disease. Fasanaro et al. 16 explain how the UPS controls the endothelial cell cycle through ubiquitination of specific protein complexes controlling the transition through the cell cycle and the exit from mitosis. In particular, the authors detail the central role played by specific and cooperative E3 ubiquitin ligases (SCF and APC/C) in this cellular mechanism and how it can be affected by oxidative stress. Stangl 19 Yu highlights the beneficial effects of proteasome inhibition in the ischaemic heart. 20 Powell's review also addresses the important and emerging concept of alteration of cardiac proteasome activity by post-translational modifications and, in particular, by oxidation. The last four reviews explore the importance of the UPS in cardiac hypertrophy and failure. As reviewed by Hedhli and Depre, 21 several reports have now shown that proteasome inhibition can prevent or reverse stress-induced as well as adaptive hypertrophy without impairing cardiac function, thereby demonstrating a necessary role for the UPS in cardiac cell growth.
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The potential mechanisms by which the UPS could interfere with protein synthesis are described in their review. Carrier et al.
25
develop the pathogenic role of UPS dysfunction in inherited hypertrophic cardiomyopathy. The authors show that the UPS is critically involved in the degradation of mutant or truncated proteins, together with the degradation of the corresponding messenger RNAs by nonsense-mediated mRNA decay. Tsukamoto et al. 26 and Luo et al. 27 review the consequences of UPS dysfunction in the transition into heart failure. In particular, Tsukamoto's contribution covers the still controversial effects of proteasome activation vs. inhibition in the context of cardiac hypertrophy and failure, whereas Luo's review addresses the very intriguing and emerging role of an immunoproteasome in the heart. Altogether, the reviews presented in this Spotlight Issue offer a far-reaching view of the multiple functions of the UPS in the cardiovascular system. They also emphasize its causal role in different forms of cardiovascular disease, and the potential of harnessing proteasome activity as a new therapeutic avenue. Although still in its infancy, this field of research is rapidly expanding; however, multiple controversies remain. Therefore, the authors also single out the important issues that remain undetermined at this point and which will have to be addressed in the future: the tissue-specific composition of the proteasome, its regulation by post-translational modifications, the expression of the immunoproteasome, the interference of the UPS with protein translation, the cooperation between UPS and autophagy, or the mechanisms controlling substrate specificity. It is likely that answering these questions will change our conception of the pathophysiology and of the treatment of cardiovascular diseases.
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